This company has been marked as potentially delisted and may not be actively trading. NYSE:NVTA Invitae (NVTA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Invitae Stock (NYSE:NVTA) 30 days 90 days 365 days Advanced Chart Get Invitae alerts:Sign Up Key Stats Today's Range$0.0003▼$0.000350-Day Range N/A52-Week Range$0.02▼$0.02Volume75 shsAverage Volume23.72 million shsMarket Capitalization$80.10 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California. Read More Invitae Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreNVTA MarketRank™: Invitae scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Invitae. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Invitae are expected to grow in the coming year, from ($1.05) to ($0.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invitae is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invitae is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvitae has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for NVTA. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInvitae does not currently pay a dividend.Dividend GrowthInvitae does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-1.13 Short InterestThere is no current short interest data available for NVTA. News and Social Media0.6 / 5News SentimentN/A Search Interest3 people have searched for NVTA on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Invitae insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.74% of the stock of Invitae is held by insiders.Percentage Held by Institutions61.28% of the stock of Invitae is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Invitae's insider trading history. Receive NVTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter. Email Address NVTA Stock News HeadlinesInvitae Corp (OTC:NVTA) Stock, Insider Trading ActivityOctober 3, 2024 | benzinga.comInvitae Launches Unlock™ Behind the Seizure® Program for Pediatric Epilepsy PatientsJuly 22, 2024 | finance.yahoo.comPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.August 10 at 2:00 AM | Paradigm Press (Ad)Invitae's $239 million sale to Labcorp approved by Bankruptcy CourtMay 7, 2024 | bizjournals.comLabcorp to acquire Invitae in strategic dealApril 28, 2024 | msn.comLabcorp to acquire Invitae assets for $239 millionApril 26, 2024 | uk.investing.comLabcorp wins $239M bid for bankrupt InvitaeApril 26, 2024 | bizjournals.comLabcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae DealApril 25, 2024 | msn.comSee More Headlines NVTA Stock Analysis - Frequently Asked Questions How were Invitae's earnings last quarter? Invitae Co. (NYSE:NVTA) posted its earnings results on Tuesday, May, 9th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.41) by $0.04. The firm's quarterly revenue was down 5.1% on a year-over-year basis. When did Invitae IPO? Invitae (NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers. What other stocks do shareholders of Invitae own? Based on aggregate information from My MarketBeat watchlists, some other companies that Invitae investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), CrowdStrike (CRWD), Teladoc Health (TDOC) and PayPal (PYPL). Company Calendar Last Earnings5/09/2023Today8/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNYSE:NVTA CIK1501134 Webwww.invitae.com Phone(628) 213-3369FaxN/AEmployees1,700Year Founded2010Profitability EPS (Trailing Twelve Months)($5.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.11 billion Net Margins-299.14% Pretax Margin-301.93% Return on Equity-6,100.71% Return on Assets-19.68% Debt Debt-to-Equity RatioN/A Current Ratio2.39 Quick Ratio2.25 Sales & Book Value Annual Sales$481.58 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book0.00Miscellaneous Outstanding Shares267,010,000Free Float284,373,000Market Cap$80.10 thousand OptionableOptionable Beta1.59 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NYSE:NVTA) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invitae Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invitae With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.